Table 1.
Baselinea characteristics for antihypertensive and antihyperlipidemic cohorts.
| Variable | Antihypertensive agents | Antihyperlipidemic agents | ||||
| Intervention (n=561) |
Control (n=1008) |
P | Intervention (n=474) |
Control (n=913) |
P | |
| Age in years, mean (SD) | 60.5 (12.9) | 59.9 (12.7) | .39 | 60.4 (11.6) | 60.6 (11.8) | .74 |
| Sex (female), n (%) | 289 (51.5) | 554 (54.96) | .19 | 229 ( 48.3) | 466 (51.0) | .33 |
| Race (white), n (%) | 556 (99.1) | 1001 (99.31) | .67 | 471 ( 99.4) | 908 (99.5) | .84 |
| Hospitalizations in previous year, n (%) | 52 (9.3) | 89 (8.83) | .77 | 46 (9.7) | 80 (8.8) | .56 |
| Emergency department visits in previous year, n (%) | 73 (13.0) | 110 (10.91) | .21 | 61 (12.9) | 90 (9.9) | .09 |
| PCP encounters per year, median (IQR) | 3.3 (2.3-5.3) | 3.3 (2.0-4.7) | .09 | 3.3 (2.0-5.0) | 3.3 (2.0-4.7) | .22 |
| Body mass index (kg/m), median (IQR) | 31.6 (28.1-35.9) | 31.1 (27.5-35.4) | .08 | 30.7 (27.3-34.7) | 30.1 (26.8-33.8) | .05 |
| Systolic blood pressure (mmHg), mean (SD) | 130.8 (12.2) | 131.0 (11.5) | .74 | 127.9 (12.0) | 128.4 (11.6) | .43 |
| Diastolic blood pressure (mmHg), mean (SD) | 76.4 (8.1) | 76.2 (8.0) | .62 | 75.1 (7.6) | 75.1 (7.4) | .91 |
| Total cholesterol (mg/dl), mean (SD) | 180.9 (34.8) | 184.6 (38.1) | .07 | 179.8 (38.4) | 182.8 (39.6) | .17 |
| High density lipoprotein (mg/dl), mean (SD) | 49.6 (14.7) | 51.3 (15.1) | .04 | 48.8 (13.3) | 50.3 (13.9) | .06 |
| Low density lipoprotein (mg/dl), mean (SD) | 100.8 (29.0) | 103.3 (32.1) | .15 | 99.0 (31.7) | 101.6 (32.8) | .16 |
| Hemoglobin A1c (%), mean (SD) |
6.8 (1.2) | 6.7 (1.0) | .32 | 6.8 (1.1) | 6.8 (1.1) | .54 |
| Charlson Comorbidity Index score, mean (SD) | 0.9 (1.1) | 0.8 (1.1) | .56 | 0.9 (1.1) | 0.8 (1.1) | .58 |
| Coronary artery disease, n (%) |
103 (18.4) | 151 (14.98) | .08 | 94 (19.8) | 177 (19.4) | .84 |
| Heart failure, n (%) | 36 (6.4) | 82 (8.13) | .22 | 27 (5.7) | 63 (6.9) | .39 |
| Hypertension, n (%) | 438 (78.1) | 794 (78.77) | .75 | 279 (58.9) | 537 (58.8) | .99 |
| Hyperlipidemia, n (%) | 321 (57.2) | 586 (58.13) | .72 | 380 (80.2) | 749 (82.0) | .40 |
| Diabetes mellitus, n (%) | 160 (28.5) | 231 (22.92) | .01 | 137 (28.9) | 224 (24.5) | .08 |
aBaseline measurements occurred on March 1, 2010, for pilot providers and July 1, 2010, for remaining participating providers.
bPrimary care physician (PCP).
cInterquartile range (IQR).
dAverage of up to three most recent readings leading up to intervention start.
eMost recent reading leading up to intervention start.